Get started

LLY

ELI LILLY: This consolidation is a buy opportunity.Eli Lilly is neutral on its 1D technical outlook (RSI = 52.880, MACD = 1.910, ADX = 25.797) as well as on 1W as for the past 7 weeks it has turned sideways. This consolidation is taking place half-way through the new bullish wave of the Channel Up that started in early 2023. As you see it is supported by the 1W MA50 and every bullish wave in the beginning was almost at +50% but the latest one was +35%. Consequently we expect a minimum of +46.22% from the bottom and that's what we're aiming for (TP = 1,095). See how our prior idea has worked out: ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NYSE:LLYLong
by InvestingScope
ELI LILLY Always a solid buy below its 1D MA50.Eli Lilly (LLY) broke on Friday below its 1D MA50 (blue trend-line) for the first time since August 09. As the stock trades within a long-term Channel Up since the March 01 2023 bottom, every time the price was below the 1D MA50, it didn't stay for long, thus providing the most effective buy entry. Even though it could dip some more as with July's decline (only such case though out of 6 corrections), as long as the 1D MA200 (orange trend-line) holds, we expect the Channel Up to be extended. The initial Higher Highs were closer to the 1.5 Fibonacci Channel extension, the last one however was exactly on the 1.0 Fib. As a result, we will take a more conservative Target on that trend-line, thus turning bullish now and aiming at $1100 by the end of the year. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot
Eli Lilly's Zepbound: A Game-Changer for Obesity Treatment?In a groundbreaking move that could redefine the landscape of obesity treatment, Eli Lilly has slashed the price of its weight loss drug, Zepbound, by half. But is this simply a strategic business decision, or is it a beacon of hope for millions struggling with obesity? Join us as we delve into the implications of this bold move and explore the potential impact on the future of weight management. Imagine a world where obesity is no longer a daunting, insurmountable challenge. A world where effective, affordable treatments are accessible to all who need them. Eli Lilly's recent announcement of a significant price reduction for Zepbound brings us closer to that reality. By making this groundbreaking decision, Eli Lilly has not only demonstrated its commitment to patient access but has also sent a powerful message to the broader healthcare industry. This move has the potential to disrupt the status quo, challenging the outdated policies and practices that have hindered progress in obesity treatment. As we explore the implications of Eli Lilly's decision, we must consider the broader context of the obesity epidemic. For decades, obesity has been stigmatized and overlooked as a serious medical condition. Many individuals struggling with weight loss have faced limited treatment options and significant financial burdens. Eli Lilly's move to lower the price of Zepbound could be a game-changer in this regard. By making the drug more affordable, the company is empowering patients to take control of their health and pursue a healthier lifestyle. This could lead to a significant increase in the number of people seeking treatment for obesity, ultimately improving public health outcomes. However, it is important to note that this is just one step in a larger journey. While Eli Lilly's decision is undoubtedly a positive development, more needs to be done to address the systemic issues that contribute to the obesity epidemic. Policymakers, healthcare providers, and communities must work together to create a supportive environment that promotes healthy eating, physical activity, and access to affordable, effective treatments. In conclusion, Eli Lilly's announcement of a price reduction for Zepbound represents a significant milestone in the fight against obesity. By making this drug more accessible, the company is not only helping individuals achieve their weight loss goals but also challenging the broader healthcare system to prioritize obesity treatment.
NYSE:LLYLong
by signalmastermind
How To Pick Top Pharma Stocks like a ProAnalyzing the pharmaceutical industry, whose products play a key role in improving the quality of life of people around the world, is quite challenging sometimes also it requires deep knowledge and a careful approach, as I believe that investors should consider many factors, starting with evaluating the efficacy of the analyzed company's medications, including in relation to its competitors and the "gold standards," and ending with an analysis of its financial indicators In this article you will learn how to pick Top Pharma stocks like a pro trader and which factors you should consider, so buckle up 1/ Recognizing the risks At the very beginning, an investor you must recognize that the pharmaceutical industry is highly competitive, where a company's investment attractiveness depends not only on the rate of expansion of its portfolio of product candidates, revenue growth, margins, the amount of total debt and cash on the balance sheet but is also heavily influenced by the expiration of patents on medications and vaccines. Moreover, in recent months, the healthcare sector has increasingly felt the impact of the upcoming 2024 US presidential elections, as some politicians are aiming to further tighten regulation of drug prices despite the existing Inflation Reduction Act. 2/ Leveraging data to your advantage The second step use data wisely, you should check all kinda data including stock screener, transcripts of earnings calls, financial results for the last quarters, analyst expectations, options data... The goal is to filter companies in poor financial condition, as well as those that trade at a significant premium to the sector and/or competitors I would also like to point out that in the current market environment, with Fed interest rates remaining at multi year highs, I do not recommend investing in companies with market caps below $500 million, as they typically have limited cash reserves and weaker institutional backing Also, I'd recommend investors read 10-Ks and 10-Qs, especially the section related to debt and sources of financing of the company's operations, to reduce the likelihood of an "unexpected" drop in the share price. A striking example is Invitae Corporation aka NVTAQ which declared bankruptcy in mid February 2024! Was there a prerequisite for this? The answer is yes since the company continued to generate negative cash flow and also had convertible senior notes maturing in 2028. Convertible notes can involve significant financial risks if the company cannot effectively use the cash to grow the business and break even. In this case, management will not be able to pay off the bonds with cash reserves and will have to resort to significant dilution of investors. In my opinion, Pacific Biosciences of California, Inc. NASDAQ:PACB may face this problem because it has convertible senior notes maturing in 2028 and 2030. Factors that concern me include the company's declining revenue and total cash and short-term investments in recent quarters, while its operating expenses remain extremely high at around $80 million per quarter. Let's return to the second step in my approach to selecting the most promising assets in the healthcare sector. When selecting companies with market caps between $4 billion and $40 billion, I use more parameters since most of them already have FDA approved drugs and/or vaccines. As a result, it is also necessary to consider the rate of growth of operating income, net debt/EBITDA ratio, and how management copes with increased marketing and production costs. Finally, let's move on to the last basket, which contains pharmaceutical companies with market capitalizations exceeding $40 billion. I think, this group is best suited for more conservative investors looking for assets offering attractive dividend yields and growing net income, supported by a rich portfolio of FDA approved and experimental drugs. So, from Big Pharma, I like Pfizer Inc NYSE:PFE , AbbVie Inc NYSE:ABBV , Merck & Co NYSE:MRK and AstraZeneca PLC NASDAQ:AZN . I also want to include Novartis AG NYSE:NVS and Roche Holding AG OTC:RHHBY in this group sometimes investors need to make exceptions, namely if one larger company buys out a smaller player and/or when a major partnership agreement is concluded, as was the case between Merck and Daiichi Sankyo Company, Limited OTC:DSKYF in 2023. Also, in the event of a major acquisition or merger, the company's debt may temporarily increase sharply. If its management has previously implemented effective R&D and financial policies, the "net debt/EBITDA ratio" A remarkable example of a company falling into the "value trap" is Takeda Pharmaceutical Company Limited NYSE:TAK , which overpaid for Shire. This deal did not significantly strengthen or rejuvenate the Japanese company's portfolio of drugs. As a result, it had to sell off billions of dollars in assets to pay off its debt partially. However, despite all the efforts of Takeda's management, its net debt/EBITDA ratio, although it fell below 5x, remains high, namely about 4.7x at the end of March 2024. 3/ Identifying promising therapeutic areas In general, the more prevalent a disease is, the larger the total addressable market for a drug and, as a result, the higher the chances that it will become a commercially successful product. Global spending on cancer medications will reach $377 billion by 2027, followed by immunology, and diabetes will come in third with an estimated spending of about $169 billion What challenges arise when choosing pharmaceutical companies? you should also keep in mind that the larger the market, the higher the competition between medicines, as companies strive to grab as big a piece of the pie as possible. As a result, for drug sales to take off, they need to have significant competitive advantages over the "gold standard." These competitive advantages may include greater efficacy in treating a particular disease, less frequent administration, a more favorable safety profile, and a more convenient route of administration. So, in recent years, competition in the global spinal muscular atrophy treatment market has intensified. Spinal muscular atrophy is a genetic condition. Currently, three drugs have been approved to combat the disorder, including Biogen Inc.'s (BIIB) Spinraza, Roche/PTC Therapeutics, Inc.'s (PTCT) Evrysdi, and Novartis AG's (NVS) gene therapy Zolgensma. All three products have similar efficacy, but Evrysdi has a more favorable safety profile and is the more convenient route of administration, namely the oral route, which is reflected in its sales growth rate from year to year. The second pitfall is the company's pipeline of experimental drugs. I believe that financial market participants opening an investor presentation that presents a company's pipeline, especially if its market cap is below $5 billion, should also pay close attention to what stage of clinical trial activity its experimental drugs are in. if a pharmaceutical company has most of its product candidates in the early stages of development, this represents a significant risk because, in this case, institutional and retail investors are often overly optimistic about the prospects for the drugs' mechanisms of action and/or clinical data obtained in a small group of patients. Simultaneously, as is often the case, the higher the optimism, the less favorable the risk/reward profile. In most cases, the larger and more diverse the patient population, the weaker the efficacy of a drug relative to what was seen in Phase 1/2 clinical trials. This ultimately leads to a downward valuation of its likelihood of approval and casts doubt on its ability to take significant market share from approved medications. This may subsequently reduce the company's investment attractiveness, making it more difficult to attract financing for its operating activities. As a result, I recommend excluding any company that, instead of focusing its financial resources on the most promising product candidates, conducts multiple early-stage clinical trials to evaluate the efficacy of its experimental drugs. In my experience, the most successful pharmaceutical companies focus their efforts on bringing up to three product candidates to market and then reinvesting the revenue from their commercialization into developing the rest of the pipeline. The table below highlights the following parameters that I use to screen out the least promising companies. A third factor that investors, especially those new to the investment world, should consider is that large pharmaceutical companies are leaders in certain therapeutic areas, with a rich portfolio of patents covering various mechanisms of action and delivery methods of drugs, making it more difficult and more prolonged for smaller players to find product candidates that could potentially have the competitive advantages. So, Novo Nordisk A/S NYSE:NVO and Eli Lilly and Company NYSE:LLY have long been leaders in the global diabetes and weight loss drugs markets, and only very recently, they may be joined by Amgen Inc. NASDAQ:AMGN , Roche Holding, and several other companies 4/ Assessing a company's drug portfolio in comparison to competitors Evaluating the effectiveness, safety profile, and mechanism of action of a medication, as well as comparing clinical data with its competitors, takes a lot of time and effort. I provided examples of drugs and the most promising mechanisms of action in the obesity treatment market. Their manufacturers are Eli Lilly, Novo Nordisk, Roche Holding, Viking Therapeutics, Inc, Amgen, Pfizer, Altimmune, Inc, OPKO Health, Inc, Boehringer Ingelheim, and Zealand Pharma A/S 5/ When market exclusivity for a company's key medications ends Every financial market participant who is considering investing in pharmaceutical companies should consider the expiration time of key patents of medicines. Marketing exclusivity represents protection against the entry of a generic version and/or biosimilar of a branded drug into the market, thereby allowing the company to recoup the resources spent on its development and, in the event of its commercial success, also reinvest the money received to accelerate the development of the remaining product candidates. Where can you find information about patent expiration dates? All the necessary information is either in 20-Fs/10-Ks or on the FDA website, namely in the "Orange Book" section. let's take Eli Lilly as an example. Open the latest 10-K. Then, the CTRL + F combination opens the ability to find specific words in the document. I usually enter "Expiry Date" or "compound patent" to find the patent section.nvestors can also find information about patents on the FDA website. As an example, I enter "Mounjaro" in the top line, and a list of patents opens that protect Eli Lilly's blockbuster from the introduction of its generic versions onto the market.hen, clicking on "Appl. No." will open information about the submission date of the patent and when it will expire. 6/ Evaluating the impact of insider share transactions The next step in selecting the most interesting assets in the healthcare sector is to analyze Form-4s. The CEO, CFO, and other key members of the company's management buy or sell shares from time to time.I am only interested in analyzing purchases since, most often, sales by management are option exercises carried out to pay taxes. When management starts making large outright purchases of a company's shares, it can signal that it believes in its long-term growth potential.if more than two top managers buy a large block of shares within two weeks of each other, it significantly increases the likelihood of the company's stock price rising in the next two months from the moment of their transactions But as with everything, there are exceptions, such as in the case of OPKO Health, which is developing a long-acting oxyntomodulin analog for the treatment of obesity together with LeaderMed Group.Over the past 12 months, OPKO's management, especially CEO Phillip Frost, has purchased over 12 million shares. However, despite this, its stock price has fallen by 27% over the same period. I believe that the key reasons for the divergence between these two facts are investors' lack of confidence in Phillip Frost's ability to make the company profitable again, as well as its low cash reserves. Therefore, companies like OPKO Health have already been eliminated at the second step of selection using Seeking Alpha's screener. 7/ CEO Performance in Business Development The CEO plays a crucial role in the success of a pharmaceutical company since the pharmaceutical industry is highly dynamic, and the competition between Big Pharma is especially high, I advise readers to pay attention to the track record of the CEO, especially how he copes with force majeure situations, as well as how effective the R&D policy is carried out under his leadership. 8/ Identifying Entry and Exit Points for Long-Term Investments The eighth step is in addition to the information that was obtained in the previous steps, as well as the analysis of financial risks and various financial metrics of the company, including its net debt, maturity dates of bonds, historical revenue growth rates, EBIT, gross margin, I build a DCF model with the ultimate goal of determining the price target. it is necessary to conduct a technical analysis of them, as well as the main ETFs that include them. In my opinion, the key ETFs are the SPDR® S&P Biotech ETF AMEX:XBI , Fidelity Blue Chip Growth ETF AMEX:FBCG , iShares Biotechnology ETF NASDAQ:IBB , and VanEck Pharmaceutical ETF $PPH. The purpose of technical analysis is to determine the stop-loss level and entry points at which the risk/reward profile is most favorable. taking profit is not that easy cuz you must master your emotions and greed which damn hard 9/ Creating a Watchlist Based on Risk/Reward Ratio The purpose of which is to create a watchlist of the companies I have selected based on the previous steps. I make several lists of companies based on their market caps and also rank them according to risk/reward profile, that is, in the first place is the stock that I think has minimal risks and at the same time can bring the greatest potential profit. I also advise creating small notes on each company, which can include information about risks, support/resistance zones, dates of publication of clinical data, and any thoughts you have that will make your decision more conscious when opening a position “What’s your secret sauce for choosing pharma stocks?”
NYSE:NVOEducation
by moonypto
ELI LILLY Recovered all losses from its High! What's next?Eli Lilly and Company (LLY) posted a miraculous bullish reversal in the past 2 weeks, recovering yesterday all of the losses of the brutal correction since its July 15 All Time High. Having rebounded on its 1D MA200 (orange trend-line) while the 1D RSI touched the 30.00 oversold barrier for the first time since February 28 2023, we can claim that LLY's Channel Up now sets eyes for its next Higher High. This pattern is best illustrated with the use of the Fibonacci Channel levels. After initially holding the 1.0 Fib as Resistance, the 'ceiling' is now the 1.5 Fib extension, basically has been since September 12 2023. The interesting parameter of this pattern is that every approximately +35.00 to +40.00% rise, the price pulls back or turns sideways (red arc pattern) until it eventually hits the 1D MA50 (blue trend-line). As the stock completes a +35% rise from the bottom, a little above the 1000 mark, we expect it to turn sideways at best. The target after that is $1200, exactly on the 1.0 Fibonacci level, which is still a modest one, considering that the ceiling is now the 1.5 Fib extension, as discussed above. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot
Eli Lilly Shares Surge Over 9% After Strong Earnings ReportEli Lilly Shares Surge Over 9% After Strong Earnings Report As the chart of Eli Lilly's (LLY) share price shows today, yesterday's trading closed at a level more than 9% higher than Wednesday's closing price. The main driver of this growth was a strong Q2 report: → Earnings per share: actual = $3.92, expected = $2.74; → Gross sales: actual = $11.3 billion, expected = $9.99 billion. Market participants reacted positively not only to the fact that the American pharmaceutical company's actual results significantly exceeded forecasts but also to Eli Lilly's rising expectations for the second half of the year, driven by demand for its diabetes treatment Mounjaro and weight loss drug Zepbound. Technical analysis of the Eli Lilly (LLY) stock chart shows that: → The price action is forming an upward channel in 2024 (shown in blue); → After a rebound, the median line of this channel was breached (as indicated by the arrow); → As could be expected, this line acted as resistance – as indicated by the high of yesterday's candlestick. What is the forecast for Eli Lilly (LLY) shares? Wall Street analysts surveyed by TipRanks remain positive – none of them recommend selling shares of the company, which has the largest market cap in the healthcare sector at over $800 billion. On average, they forecast that LLY shares will reach $955 within 12 months. This suggests that the current upward channel may remain relevant. However, it’s possible that: → The lower boundary will continue to act as support; → The boundaries of the bullish gap formed at yesterday's opening may also provide support. A similar action can be seen on the chart – after a wide bullish gap (also formed following a strong report) on 30 April, LLY shares found support near the lower boundary of that gap around $740. This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
NYSE:LLY
by FXOpen
2
Is Eli Lilly's Stock in a Bubble or just a Correction?Eli Lilly & Co. (NYSE: NYSE:LLY ) has been a standout performer in the stock market this year, with its stock price surging by around 50%, far outperforming the S&P 500’s 15% rise. This impressive performance has brought the stock to trade at 63 times its projected 2024 earnings of $13.75 per share. This raises a critical question for investors: Is Eli Lilly's stock overvalued, or is there still room for growth? Stellar Growth Driven by Innovative Drugs Eli Lilly's recent surge can be attributed primarily to the high demand for its obesity drug, Zepbound, and its diabetes drug, Mounjaro. These two drugs alone are expected to bring in $50 billion in annual peak sales. The company is currently facing a shortage of Zepbound and plans to invest $9 billion in a new manufacturing facility to meet this demand. Additionally, Eli Lilly’s pipeline is extensive, with several drugs under clinical trials across various therapeutic areas. One notable approval is Donanemab, an Alzheimer's Disease treatment, which could generate $5 billion in peak sales. Other successful drugs, such as Verzenio and Zyprexa, also contribute to the company’s robust revenue growth. Financial Performance and Future Projections Eli Lilly's revenue is projected to grow from $34 billion in 2023 to over $60 billion by 2026, representing an increase of over 75%. The company's earnings are also expected to more than triple during this period. Despite a 12% decline in net income from $6.2 billion in 2020 to $5.2 billion in 2023, mainly due to increased non-operating expenses and acquisitions, the adjusted net income margin is poised for a rebound. In Q1 2024, Eli Lilly ( NYSE:LLY ) reported an adjusted net margin of 26.6%, up over 500 basis points year-over-year. The company’s investments in R&D and product development are starting to pay off, and adjusted earnings are expected to range between $13.50 and $14.00 per share in 2024, more than double the previous year. Considering these projections and expected margin expansions, Eli Lilly’s adjusted EPS could reach $25 by 2027. If the stock price remains constant, the forward P/E multiple would decrease to 34x in 2026. However, investors are betting on the stock price increasing, resulting in a more modest P/E contraction to about 52x. This scenario would imply a 50% growth in Eli Lilly's stock price to approximately $1,300 over the next three years. Risks and Competition Despite the positive outlook, Eli Lilly faces risks, particularly from increasing competition in the obesity drug market. Competitors like Novo Nordisk, Roche, and Amgen are also making strides in weight-loss treatments. However, the obesity drugs market is projected to grow 16-fold to over $100 billion by 2030, with Eli Lilly and Novo Nordisk likely dominating this space. Is Eli Lilly's Stock in a Bubble? The term "bubble" implies a scenario where asset prices are inflated beyond their intrinsic value, often driven by speculation and a belief that prices will never fall. While Eli Lilly’s stock has seen tremendous gains, rising 656% over the past five years compared to the S&P 500’s 78.4% increase, it does not necessarily mean it is in a bubble. Eli Lilly’s rise is backed by strong fundamentals, significant revenue growth, and promising developments in its drug pipeline. Conclusion Eli Lilly’s stock is not just a result of speculative trading; it is supported by solid business performance and growth prospects. While there are competitive risks, the company’s innovative drug portfolio and strategic investments position it well for continued success. Any dip in Eli Lilly’s stock should be seen as a potential investment opportunity, offering robust long-term gains. The next few years will likely see Eli Lilly continue its upward trajectory, driven by market share gains and regulatory approvals.
NYSE:LLY
by DEXWireNews
Eli Lilly's Alzheimer's drug Kisunla wins FDA approvalEli Lilly & Co.'s new Alzheimer's disease drug, Kisunla, has received approval from the US Food and Drug Administration (FDA), marking a significant advancement in treating the disease. This approval positions Kisunla as the second drug available that can slow the progression of Alzheimer's, a condition affecting around 6 million Americans. Kisunla's journey to market has been fraught with regulatory hurdles, including the FDA's initial reluctance to fast-track the drug based on early trial results, preferring instead to review late-stage data. This thorough scrutiny culminated in a one-day hearing earlier this year to deliberate on Kisunla's safety and efficacy, eventually leading to its approval. Kisunla will now compete with Eisai Co.'s Leqembi, which has been available in the US since early 2023. Technical analysis of Eli Lilly & Co. (NYSE: LLY) Exploring potential trading opportunities, let us review the technical aspects of Eli Lilly's stock: Timeframe: Daily (D1) Current trend: there is an observable uptrend, though the stock has recently broken the support level at 905.00 USD and is attempting to consolidate below it Resistance level: 917.00 USD New support level: after breaking 905.00 USD, further confirmation is necessary to establish new support Potential downtrend target: if a downtrend is established, the downside target could be around 820.00 USD Short-term target: if the uptrend resumes and the stock price breaks through the resistance at 917.00 USD, a short-term target could be set at 940.00 USD Medium-term target: should the upward momentum be sustained, the price might rise to 960.00 USD Investors should closely monitor Eli Lilly’s performance, especially in light of the recent FDA approval of Kisunla. This development could significantly impact the company's market position and stock performance in the pharmaceutical sector. — Ideas and other content presented on this page should not be considered as guidance for trading or an investment advice. RoboMarkets bears no responsibility for trading results based on trading opinions described in these analytical reviews. The material presented and the information contained herein is for information purposes only and in no way should be considered as the provision of investment advice for the purposes of Investment Firms Law L. 87(I)/2017 of the Republic of Cyprus or any other form of personal advice or recommendation, which relates to certain types of transactions with certain types of financial instruments. Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69.88% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
NYSE:LLYLong
by RoboMarkets
ELI LILLY Entering consolidation phase. Wait for the buy signal.Last time we looked at Eli Lilly (LLY) was on March 18 (see chart below) and we got the most out of it as we entered after a 1D MA50 correction and got the most optimal value: Our original target was $1050 calculated according to the % rise of each previous Bullish Leg (+45%) of the +1 year Channel Up but now it appears that the stock won't hit that level during this Leg as we are entering the bottom phase of the Sine Wave. As you can see on the chart (now on the 1W time-frame), this is where LLY typically pulls-back and consolidates (red Rectangle) until the next Bullish Leg begins near the 1D MA100 (red trend-line). As a result, we are closing our bottom buy position and turn neutral on LLY until we approach the 1D MA100 again, starting mid-August. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLY
by TradingShot
1
$LLY look out below $265 bottom coming soonNYSE:LLY looks like it's topping up here. Anytime you see a chart that has gone straight up like this, you know the fall is going to be painful. I think we'll top within the next week or two and then we're going to start the bear market that goes all the way down to $265 before it truly bounces. Why do I think this? If you create a parabola, price is starting to break through it which means we're likely to see a 80%+ correction once the trend changes. On top of this, RSI is in extreme overbought territory. If you're long, I'd set stops where you're comfortable with gains because once this move down happens, months worth of gains will evaporate.
NYSE:LLYShort
by benjihyam
2
ELI LILLY Preparing for the final buy opportunity.Eli Lilly is on a very steady bullish technical outlook on the 1D timeframe (RSI = 62.145, MACD = 9.380, ADX = 18.580) as it has been trading inside a Channel Up since January 2023. The current bullish vessel within this pattern is a Rising Wedge. As you can see, the two Wedges prior have a last break under the 1D MA50 before rallying to a HH at the top of the Channel Up. The 1D RSI has already crossed over its LH trendline so every pullback that comes in the next 2 weeks, is in our opinion the last buy opportunity. Our target is approximatelly a +45% rise (TP = 1000) which is the rise that all bullish structures prior experienced. See how our prior idea has worked out: ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NYSE:LLYLong
by InvestingScope
BMY- a large cap pharm loosing market cap SHORTBMY is here on the daily chart. The double top and death cross of the EMA moving averages makes for a strong candidate to short with shares or take put options. A comparsion of the most recent earnings report with the previous one sixty days earlier tells most of the story. The dual time frame RSI indicator shows ongoing wekaness. I will short BMY here and take some call options as well. I am in LLY long in a big position. This will be a race in opposite directions for two large cap pharmaceuticals.
NYSE:BMYShort
by AwesomeAvani
✏️ Weekly Report: Volatility makes Cash the King againGENERAL COMMENTS Today, the Federal Reserve maintained its interest rates unchanged, highlighting the ongoing challenges in curbing inflation. Initially, this announcement propelled the markets upwards, but a sharp downturn occurred in the final hour, leading to a decline as the day concluded. The erratic market behavior demonstrated today makes it increasingly challenging to maintain positions in momentum stocks, and the majority of this quarter's earnings reports have been underwhelming. This situation underscores the strategy that cash remains paramount, complemented by selective, quick trading opportunities, as depicted in the following charts. I will begin tonight's chart analysis with the Nasdaq-100 (QQQ). NASDAQ:QQQ The Qs are forming a bearish formation. What is worrying is that this is below the 50D Simple Moving average. As trading is a probabilities game, we can conclude that this leads to probabilities being lower that we continue to the downside. However, the direction of the general market indexes are very well influenced by the fundmental story of the economy health. –––––––––––––––––––––––––––––––––––––––––––––––––––– NASDAQ:SMTC SMTC is up $4 from the $33 Buy Point (alerted in previous versions of this idea - go and check. Believe and Follow). This peaked yesterday with about +20% profit since the alert last week. Of course the way I manage this is never to let this to turn into a loss. My general go to tool is to take half here. –––––––––––––––––––––––––––––––––––––––––––––––––––– NASDAQ:KLAC KLAC fell back to $687 after missing earnings. This of course stopped me out - but at no loss, since I move stopped up to break-even. –––––––––––––––––––––––––––––––––––––––––––––––––––– NASDAQ:SMCI The stock missed its earnings and suffered a severe reaction of a gap down and drop -20% on the intraday. –––––––––––––––––––––––––––––––––––––––––––––––––––– NASDAQ:NVDA NVDA slashed below the 50D SMA and this stopped me out. Waiting and watching this TML during its base building period. –––––––––––––––––––––––––––––––––––––––––––––––––––– NYSE:GS Up $7 from the $419 buy point with stop raised to $416 just in case. –––––––––––––––––––––––––––––––––––––––––––––––––––– NYSE:CRM CRM is prone to go lower if the market continues falling. A break below $266.50 is great place to short. –––––––––––––––––––––––––––––––––––––––––––––––––––– NYSE:LLY Gapped up on good earnings. The next technical buy point is $801 accommodated with heavy volume. –––––––––––––––––––––––––––––––––––––––––––––––––––– NASDAQ:MRNA Earnings are due out tomorrow. If earnings are good then zooming through the $116 on good volume is a great technical buy point
NASDAQ:QQQ
by SimplerSignals
Eli Lilly's Stock Surges 4.77% on Weight-Loss Wonder DrugEli Lilly & Company (NYSE: NYSE:LLY ) has sent shockwaves through the pharmaceutical industry with the meteoric success of its weight-loss drug Zepbound, propelling the company's stock to new heights despite a mixed first-quarter performance. With sales of Zepbound surpassing Wall Street's projections by a staggering margin, Eli Lilly has raised its sales outlook for the year, overshadowing slight revenue dips from other key products. Zepbound's Triumph and Guidance Boost: In a remarkable turn of events, Zepbound emerged as the star performer in Eli Lilly's ( NYSE:LLY ) portfolio, surpassing sales forecasts by a substantial margin. With first-quarter sales reaching $517.4 million, well above the expected $373 million, Zepbound's success has prompted Eli Lilly to raise its sales guidance for the year by a staggering $2 billion. This unexpected surge in demand for the weight-loss drug has underscored Eli Lilly's position as a frontrunner in the pharmaceutical industry and has reignited investor confidence in the company's growth prospects. Challenges and Opportunities in the Diabetes Market: While Zepbound's success has captured headlines, Eli Lilly ( NYSE:LLY ) faces challenges in its diabetes portfolio, particularly with drugs like Mounjaro and Trulicity. Despite a surge in sales for Mounjaro, both drugs fell short of analyst expectations, highlighting the competitive landscape in the diabetes market. However, with plans to expand production significantly in the second half of the year, Eli Lilly remains optimistic about its ability to meet the growing demand for diabetes treatments and capitalize on emerging opportunities in the market. Analyst Insights and Market Response: Analysts have offered mixed assessments of Eli Lilly's performance, with some highlighting the company's robust guidance raise and the continued strength of Zepbound, while others have raised concerns about softer sales in the GLP-1 franchise. However, overall sentiment remains positive, with analysts reaffirming their bullish outlook on Eli Lilly's stock and emphasizing the company's strategic initiatives to drive growth and innovation. Looking Ahead: As Eli Lilly ( NYSE:LLY ) charts its course forward, all eyes are on the continued success of Zepbound and the company's ability to navigate challenges in the diabetes market. With a bolstered sales outlook and a commitment to expanding production capacity, Eli Lilly ( NYSE:LLY ) is poised to capitalize on evolving consumer preferences and emerging opportunities in the pharmaceutical landscape.
NYSE:LLYLong
by DEXWireNews
LLY, LILLY IS THIS STOCK PRICE SILLY?I hope you appreciated my rhyme. So what to say about this. One main trend line at the moment. Big support incoming at 580 to 560 range. Really big support at 108. The lines in the middle (light green and red) are fairly weak and more likely short term targets. I assume the long term targets will line up well with the gaps which are marked in orange. Orange also on RSI, which is saying be careful. Short term can take it up to 980 or so but I think the lower targets are more likely and we'll see the higher targets after trend breaks and before it starts to really drop. However, there are a lot of possibilities that can occur. The main possibility looks to be a chance of a move to 980, but more likely won't get there and might stick around 780. I really have a hard time saying what this will do and when it will top out, I could tell you more if I watched this daily, but I don't. This chart is long term price targets for the downside and the upside. Given the single trend, you'll need a new chart as more develop, feel free to message if I haven't updated after some time. I think that covers most everything. Summary. I think this stock is overvalued big time, but still has potential to keep seeing more upside in the short and mid term.
NYSE:LLY
by nicktussing77
ELI LILLY Going to $1050 but after a 1D MA50 correction.Eli Lilly (LLY) has basically turned sideways since the February 16 High. The dominant pattern is a Channel Up since the March 07 2023 Low and can be divided into 3 Bullish Waves that delivered rallies between +45% and +52%. Every time the price hit the 1D MA50 (blue trend-line), it was a buy opportunity. The 1D RSI in particular has a Buy Zone, which coincided with all those dip buy opportunities within the Channel Up. As a result, since the stock has already completed a +45% rise from the October 31 2023 Low, we do expect a pull-back to start soon towards the RSI Buy Zone, but only after it rises a little again and forms a Lower High on the RSI, which would be consistent with the previous top formation on the Channel Up. In any case, at any point the RSI hits its Buy Zone, we will position ourselves with a long and aim for a new +45% rise. Rough target from the current projection is $1050. Notice how efficiently the peak and bottom formations are caught by the Sine Waves. A very symmetric pattern for the long-term indeed. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLY
by TradingShot
LLY rides its success against obesity and diabetes LONGLLY shown on a daily chart has doubled in the past year with the introduction of new FDA approved drugs into the market. It has but out a series of favorable earnings reports with optimistic realistic guidance and glowing analysts' forecasts. It has done so without any volume pumps and just keeps grinding higher. This is because it is in the shadows of big technology stocks. Revenues consistently beat analysts' forecasts quarter after quarter. Institutions add small lots trying to preserve the price for future buys without any run-ups. I have done the same thing and I will continue to do so. While day trading biotechnology penny stocks, LLY along with UNH, PFE, and AZN is where the profits are parked for growth and compounding.
NYSE:LLYLong
by AwesomeAvani
1
ELI LILLY Is a -20% correction possible?Eli Lilly (LLY) gave us the best possible buy entry at the bottom of the Channel Up last time we gave a call on it (December 14 2023, see chart below) and not hit our $705.00 Target but also aggressively broke above the pattern: In order to grasp the magnitude of that move, this time we zoom out on the 1W time-frame where we see the long-term pattern since LLY's parabolic move started, in mid 2018 following 3 years of consolidation. The pattern that emerged since is a 6-year logarithmic Channel Up, which since 2023 has gone extremely parabolic. The key characteristic on this long-term price action is the unique pattern that the 1W MACD forms, a Bearish Cross followed by a Bullish Cross. Four such occurrences since 2018 have caused the stock to form a Higher High top at a minimum 2 weeks and maximum 10 weeks after the Bullish Cross. Currently we are on the 3rd week since the latest 1W MACD Bullish Cross and if it extends to 10 weeks, we can technically expect the new top by April 08 2024. However, the 1st red 1W candle following the Bullish Cross on those 4 past occurrences has always been the top, or near it. Given the fact that LLY is so close to the top of the 6-year Channel Up, we can expect that a correction will start soon. The minimum correction has been -17.44% and the maximum -23.23% (2 occasions out of the 4). Also before a new long-term rally started, the price hit the 1W MA50 (blue trend-line). Long-term investors can wait for such a contact before buying again heavily Eli Lilly for a new 12-month run. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLY
by TradingShot